Kornimate/medical-research-clean huggingface dataset:
operation of brain stimulation equipment under remote viewing effectiveness registry

Conditions: Major Depressive Disorder; MDD; Generalized Anxiety Disorder; GAD; Depression; Anxiety

Summary: the goal of this observational study is to record and analyze factors putatively affecting the clinical outcomes among patients undergoing transcranial magnetic stimulation (tms) treatment for major depressive disorder (mdd) or generalized anxiety disorder (gad). the main questions it aims to answer are: 1. which factors have the greatest causal role in mediating the effectiveness of tms in improving symptoms of depression (and/or anxiety)? 2. which factors have a minimal causal role in mediating the effectiveness of tms in improving symptoms of depression (and/or anxiety)? participants already undergoing tms as part of their treatment plan for mdd/gad answer survey questions about their symptoms before, during, and up to 1 year post-treatment. factors affecting clinical outcomes such as stimulation parameters, behavioral factors, physiological factors, patient characteristics, and pharmacological factors, are also recorded.


Eligibility criteria:
inclusion criteria: * have a primary diagnosis of major depressive disorder (mdd) and/or generalized anxiety disorder (gad) * are receiving outpatient care, * voluntarily provide competent consent for treatment, * are 12 years of age or older, * are able to adhere to the weekly assessment schedule for primary outcome measures, * have been assessed by their prescribing physician as suitable candidates for tms treatment in terms of safety and presenting indication, * have consented to undergo a therapeutic course of tms treatment at one of the participating clinic sites, * are able to communicate in the english language. exclusion criteria: * have been found to have any contraindication to tms treatment by their prescribing physician, * are considered unsuitable for outpatient care due to illness severity or other factors in the opinion of their prescribing physician, * have active suicidal intent or plan, * are unable to adhere to or decline participation in the weekly assessment schedule for primary outcome measures, * lack the ability to communicate in the english language.

Keywords: transcranial magnetic stimulation tms noninvasive brain stimulation accelerated protocol stimulation parameters patient health questionnaire behavioral factors physiological factors generalized anxiety disorder 7-item scale phq-9 phq9 gad-7 gad7 longitudinal observational study registry patient characteristics pharmacological factors united states of america usa, us canada hamilton depression rating scale montgomery-asberg depression rating scale hamilton anxiety rating scale generalized anxiety disorder 10-item scale for adolescents gad-10-a, gad-10a, gad10, gad10a patient health questionnaire for adolescents phq-9a, phq9a
connecting low-income adults to primary care after inpatient discharge

Conditions: Health Care Utilization; Health Care Seeking Behavior

Summary: healthcare systems and insurers have tried to reduce costs by improving the care and coordination provided to patients with high healthcare spending. often termed, "hotspotting", these interventions seek to lower costs by reducing care provided in fragmented, high-cost settings, including the emergency department and inpatient settings, by addressing the social determinants of health and improving patients' access to lower-cost, ambulatory settings. vanderbilt university medical center (vumc), in collaboration with tennessee's medicaid agency (tenncare), is piloting a program to reduce costs and improve the quality of care provided to high-risk tenncare enrollees by referring them from inpatient settings to vumc primary care services. this study seeks to evaluate this pilot by comparing outcomes between medicaid patients referred to vumc primary care services and similar medicaid patients not referred to vumc primary care services using data from surveys and administrative sources, including electronic health records and health insurance claims.


Eligibility criteria:
inclusion criteria: * age 18 or older * currently enrolled in tennessee's medicaid program (tenncare) * presenting in vumc's inpatient setting * reporting no active relationship with a primary care doctor * lives in davidson county, tennessee, or a surrounding county exclusion criteria: * patients discharged to a setting other than the community (e.g. to a skilled nursing facility)

Keywords: health care costs hospitalizations emergency department use health care accessibility medicaid low-income populations
a tear-based, lab-developed test for breast cancer for women with dense breast tissue

Conditions: Breast Cancer Screening

Summary: investigation of a tear-based, lab-developed biological test for breast cancer, as a supplemental tool to current screening recommendations for women with dense breast tissue will explore if a tear-based biological test can be used as a support tool in the breast cancer screening protocol for women with dense breast tissue. the test was designed and validated by namida lab, inc., a high complexity clinical laboratory improvement amendments (clia) certified lab.


Eligibility criteria:
inclusion criteria: categorized as having heterogeneously dense or extremely dense tissue 18 years of age or older able to understand the informed consent process willing to comply with all study procedures exclusion criteria: have an active eye infection categorized as having fibro glandular densities or fatty breast tissue currently diagnosed or are receiving treatment for breast cancer under 18 years of age
risk of life-threatening heart rhythm disturbances in siblings

Conditions: Defibrillators, Implantable; Myocardial Infarction; Tachycardias, Ventricular

Summary: the purpose of this study is to determine if heredity influences the risk of life-threatening heart rhythms (ventricular tachycardia and ventricular fibrillation) after heart attack (myocardial infarction).

greater than 400,000 persons die suddenly each year in the us. the implantable cardioverter-defibrillator (icd) has revolutionized the primary prevention of sudden cardiac death (scd) following myocardial infarction (mi), however, risk stratification remains limited and rests solely on the identification of left ventricular dysfunction. the goal of this study is to determine if genetic factors influence the risk of ventricular arrhythmia remotely after myocardial infarction. in order to determine if ventricular tachycardia or ventricular fibrillation remotely after mi is a heritable trait, we will conduct a family based case-control sibling study of patients who have received an icd for ischemic cardiomyopathy. as a first step, we will utilize the genecard registry, an existing family linkage study of premature cardiovascular disease, to determine the prevalence of sibling concordance for icd implantation following mi. probands and siblings in the genecard study will be surveyed regarding their icd history. the sibling recurrence risk ratio for icd implantation following mi and subsequent icd therapies will be used to estimate the sample size required to validate heritability, in a larger patient population. in the validation phase of this protocol, we will use a (1) single healthcare system database (duke cardiovascular databank) and a (2) regional population-based registry, in order to determine concordance for icd therapies. patients who agree to participate and provide informed consent will be surveyed regarding their personal icd history and that of their siblings. the prevalence of icd therapies will be ascertained in the probands, siblings, and the overall cohort. sibling concordance for icd implantation and sibling concordance for subsequent appropriate icd therapies will be used to determine the sibling recurrence risk ratio for appropriate icd therapies remotely after mi.

Eligibility criteria:
inclusion criteria: * patients must be alive * have a history of coronary artery disease / myocardial infarction * left ventricular ejection fraction ≤ 35% * received an implantable cardioverter- defibrillator exclusion criteria: * nonischemic cardiomyopathy * pre-identified hereditary arrhythmia syndrome (e.g. long qt syndrome, brugada syndrome, etc) * left ventricular ejection fraction \>35% * no implantable cardioverter-defibrillator

Keywords: implantable cardioverter-defibrillator ischemic cardiomyopathy ventricular arrhythmias sibling concordance
ckd-828 (80/5mg) pharmacokinetic study

Conditions: Hypertension

Summary: a randomized, open-label, single-dose, four-period, two-way, crossover study,

a randomized, open-label, single-dose, four-period, two-way, crossover study to compare the pharmacokinetics and safety ckd-828 (fixed dose combination tablet) to coadministration telmisartan and s-amlodipine in health volunteers.

Eligibility criteria:
inclusion criteria: * a healthy volunteer over 20 years old * more than 50kg and within 20% of ideal body weight * no any congenital or chronic diseases and medical symptom * appropriate for the study from examination(laboratory test, ecg etc.) within 4weeks prior to the first ip administration * signed the informed consent form prior to the study participation. exclusion criteria: * history of relevant hypersensitivity against drug * clinical significant disease or medical history (ex. hepato/cholangio, cardio, endo, hemato, onco, cns etc.) * active liver disease or abnormal laboratory result (ast or alt or total bilirubin \> 1.5\*uln) * sbp \ 150mmhg * dbp \ 100mmhg * creatinine clearance \<80ml/min * a disease(ex.inflammatory intestinal disease, gastric or duodenal ulcer ,hepatic disease history , gastro-intestinal surgery except for appendectomy)that may influence on the absorption, distribution, metabolism and excretion of the drug * the evidence of severe attack or acute disease or surgical intervention within 28 days prior to the first ip administration. * a drug abuse or a heavy caffeine consumer (more than 5 cups per a day) or regular alcohol consumer(more than 21 units/week) or a heavy smoker(more than 10 cigarettes per a day) * taking etc medicine or oriental medicine within 14days or taking otc medicine within 7days prior to the first ip administration * abnormal diet(especially, grapefruit juice within 7 days prior to the first ip administration) that may influence on the absorption, distribution, metabolism and excretion of the drug

Keywords: hypertension ckd-828 telmisartan s-amlodipine pharmacokinetic
examinations of tissue from ablated malignant liver metastases as predictors of outcome

Conditions: Liver Cancer

Summary: the purpose of this study is to see if the investigators can do some tests on tissue from the area of the ablation. the investigators want to know if a test can help predict whether the ablation worked. the treated tumor is normally evaluated with ct. the ct shows signs of treated tumor(s) in the area treated by ablation. however, cancer cells may begin to grow in or near the treated area. the ct scan cannot tell us if the cells are new cancer cells or if they are healthy liver cells that just look different because of the ablation. the test the investigators will study should be able to tell us the difference.


Eligibility criteria:
inclusion criteria: * patients with diagnosed with secondary hepatic malignancy; * patients with confined liver disease or stable limited extrahepatic disease; * lesions of 5cm or less in maximum diameter; * patients who are not surgical candidates or refuse to undergo surgery and choose any percutaneous ablation as an alternative treatment option. * inr\<1.5 \*for patients on coumadin general clinical guidelines for ir ablation will be followed. * platelet count \> or = to 50,000 exclusion criteria: * patients \< 18 * less than 5 mm distance of the tumor margin from a major vessel \>7mm in diameter)\*\* * less than 5 mm distance to a structure (gi or biliary tract), that cannot be protected from\*\* * the ablation injury with technical modifications such as hydro or air dissection. * inr \> 1.5 that cannot be corrected with fresh frozen plasma\* * platelet count of \<50,000 that cannot be corrected with transfusion. * patient with more than 3 tumors treated with any percutaneous ablation * patients with more than 5 sites of extrahepatic disease (including nodes and pulmonary nodules) * for patients on coumadin general clinical guidelines for ir ablation will be followed \*\*this will not be considered an exclusion criteria when ire or microwave is used. * this will not be considered exclusion when ire is used

Keywords: liver thermal ablation dynamic ct 09-122
dynamic blood inflammatory profile in atopic dermatitis patients (adamune)

Conditions: Atopic Dermatitis

Summary: this is a prospective, single-center, class 2 study to better characterize the immune response in immune response in the blood of atopic dermatitis. investigators are following in the referral center of nice, 100 patients with atopic dermatitis. investigators plan to include 30 patients. blood samples will be collected to assess cytokine levels after non-specific immune stimulation. immune stimulation. whole blood will be collected and stimulated with immune ligands (anti-cd3 t-cell stimulating ligands associated with thymic stromal lymphopoietin (tslp) or tlr agonist r848 7/8 agonist stimulating nk (natural killer) lymphocytes and promoting t cell response) on lyophilized freeze-dried spheres (lyosphere, qiagen) within 8 hours of blood collection.


Eligibility criteria:
inclusion criteria: * patient aged ≥ 18 years. * patient with clinically diagnosed atopic dermatitis according to the criteria of hanifin and rajka. * moderate to severe defined by an investigator's global assessment ³3 and eligible to systemic treatment. * if the subject is a woman of childbearing potential, she has a negative urine pregnancy test. * subject is non-pregnant, non-lactating and is not planning for pregnancy during the study period. * subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair his/her evaluation or which exposes the subject to an unacceptable risk by study participation. * subject is able to comprehend and willing to sign an informed consent and/or assent form. * affiliation to a social security scheme. * signed informed consent exclusion criteria: * vulnerable person: pregnant or nursing woman, minor, adult under guardianship or deprived of liberty * patient with an infection * patient with other systemic inflammatory disease * patient with anti-inflammatory or immunosuppressive therapy * patient with a contraindication to jak inhibitors * participants in other clinical therapeutic studies involving a drug that may interfere with the present evaluation
fixed low-dose simethicone combined with macrogol 4000 (peg) reduces colon bubble formation in colonoscopy

Conditions: Colorectal Cancer; Colonoscopy; Bowel Preparation Solution

Summary: several randomised studies have shown that the addition of low-dose simethicone to the bowel preparation was sufficient to reduce the presence of bubbles during colonoscopy. the aim of this study was to evaluate the efficacy and safety of a bowel preparation containing low-dose simethicone on bubble formation. patients and methods this prospective, real-life, phase 4 study was conducted from february 2020 to may 2021, in five private endoscopy centres, among adult patients undergoing a colonoscopy. clinical, endoscopic and histological parameters were collected on e-crf. the primary endpoint was the measurement of bubble formation in the various colon segments.


Eligibility criteria:
inclusion criteria: patients : * scheduled for colonoscopy as part of crc screening, using the bowel preparation with fixed low-dose of simethicone combined with macrogol 4000 (peg) * aged 50-75 years, * with no family history of crc or personal history of colon polyps but with a positive faecal immunochemical test (fit), with a family history of crc or personal history of colon polyps, * requiring surveillance colonoscopy after 5 years if diagnosed with one or two tubular adenomas \<10 mm in diameter (low-risk group) or after 3 years if diagnosed with at least 3 adenomas or any adenoma at least 10 mm in diameter or with high-grade dysplasia, according to french recommendations during the study inclusion period. exclusion criteria: -
desflurane and sevoflurane on remifentanil requirement

Conditions: Spinal Diseases

Summary: the primary purpose of this study is to compare the desflurane and sevoflurane on remifentanil requirement using analgesia nociception index-guided anesthesia in patients undergoing spine surgery.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of herniated disc, injury of spinal cord, and neoplasm of spinal meninges exclusion criteria: * hyperbilirubinemia * prior chronic pain * prior opioid abuse * cardiac arrythmia
heard (long term) study - histology of the esophagus in acid-related disease

Conditions: Gastroesophageal Reflux; Heartburn; Dyspepsia

Summary: determine if different levels of acid-suppression with esomeprazole for 6 months on chosen histological markers of esophageal epithelial acid-related disease in patients with upper gi symptoms.


Eligibility criteria:
inclusion criteria: * signed informed consent * 18 years or older * history of upper gi symptoms exclusion criteria: * peptic ulcer disease * upper gastrointestinal surgery * malignancy

Keywords: immunohistochemical erosive esophagitis acid reflux disease
new microprocessor-controlled prosthetic knee evaluation

Conditions: Lower Limb Amputation Above Knee (Injury)

Summary: the target of this clinical investigation is to compare the achievement of personal functional goals using a new mpk and current mpk. subjects will also run functional tests and questionnaires to compare performances and feedback with each prosthetic knee.


Eligibility criteria:
inclusion criteria: * able to understand and give informed consent * man or woman, more than 18 y.o * lower limb amputee kd or aka, unilateral or bilateral * k3/k4 activity level * already fitted with fr-reimbursed mpk * being comfortable in their socket (scs\>=5) exclusion criteria: * protected person * pregnant or breast feeding lady * person having pathologies affecting their sensitivity * using walking aids * weighting more than 136kg * insufficient hip joint or pelvic voluntary muscle control * insufficient cognitive ability to charge the knee and care for the device

Keywords: micro-processor controlled knee lower limb prosthesis patient-specific functional scale
effect of insulin on endothelin-dependent vascular tone in the forearm circulation

Conditions: Hyperinsulinemia

Summary: previous studies have shown that insulin may stimulate the release of endothelin (et) from endothelial cells. this mechanism may contribute to the adverse vascular effects determined by chronic hyperinsulinemia. the aim of this study will be to evaluate the effect of local hyperinsulinemia on et activity in the forearm circulation. to this purpose, we will assess the forearm blood flow response to et receptor antagonism in control conditions and during intraarterial infusion of insulin. we will also measure changes in plasma et-1 levels in response to the different pharmacological stimuli.

previous studies have shown that insulin may stimulate the release of endothelin (et) from endothelial cells. this mechanism may contribute to the adverse vascular effects determined by chronic hyperinsulinemia. the aim of this study will be to evaluate the effect of local hyperinsulinemia on et activity in the forearm circulation. to this purpose, we will assess the forearm blood flow response to et receptor antagonism in control conditions and during intraarterial infusion of insulin. we will also measure changes in plasma et-1 levels in response to the different pharmacological stimuli.

Eligibility criteria:
between 40-65 years old. no medications. no medical problems. no serum cholesterol levels below 200 mg/dl. no contraceptives.

Keywords: bq-123 endothelin insulin plethysmography vasoconstriction healthy volunteer
multi-modal imaging of myofascial pain

Conditions: Myofascial Pain

Summary: the goal of this study is to develop new imaging biomarkers for quantitative assessments of myofascial pain.

this study aims to develop a multi-modal, multi-parametric, multi-scale imaging of the human myofascial unit by combining magnetic resonance imaging (mri), surface electromyography (semg), and fiber-optic imaging and sensing. participants (half with active neck/shoulder/back pain, and half healthy controls) will be recruited from pain management clinics and volunteer for health, or will be referred by dr. xioabin yi. they will undergo all three imaging techniques and complete a number of patient questionnaires over the course of a single study visit. the study team will then identify candidate biomarkers capable of differentiating between healthy (no myofascial pain) and those with active pain to target in a future clinical trial.

Eligibility criteria:
healthy volunteer inclusion criteria: 1. absence of a history of chronic pain in the targeted anatomical location (i.e., neck and shoulder) that had limited activities of daily living or work 2. a numerical current pain index of lower than 0.5 according to initial assessment with visual analog scale 3. able to understand the goal of the project and give informed consent. healthy volunteer exclusion criteria: 1. pregnancy or breastfeeding 2. contraindication to mri 3. previous severe/acute neck or shoulder injury 4. previous neck or shoulder surgery 5. neck or shoulder deformities 6. inability to provide consent. myofascial pain patient inclusion criteria: 1. between the ages of 18 and 80 years old 2. neck and/or shoulder pain, unilateral or bilateral 3. duration of symptoms for longer than 4 weeks 4. pain scale at the active state higher than 4 according to initial assessment with visual analog scale 5. presence of active trigger point(s) according to palpation and/or presence of taut band myofascial pain patient exclusion criteria: 1. recent history of trauma to the neck (e.g., whiplash) 2. acute cervical radiculopathy 3. acute cervical spine pain component or acute cervical spinal pathology presence of neuromuscular pathologies or inflammatory muscle diseases (e.g., dermatomyositis) 4. systemic disease with diffuse body pain (e.g., system lupus erythematosus and and thyroid disease) 5. peripheral neuropathy 6. cancer-related pain 7. pregnancy, coagulopathy, fever, general/local infection at the pain site, substance abuse, peripheral neuropathy, or any other diseases that may account for signs and symptoms mimicking myofascial pain 8. contraindication to mri.

Keywords: magnetic resonance imaging surface electromyography fiber-optic imaging and sensing
comparative effects of kt and pg on ue lymphedema and functional disability after mastectomy

Conditions: Lymphedema of Upper Limb

Summary: to compare the effects of kinesio taping and compression garmets on the upper extremity lymphedema,functional disability and quality of life after mastectomy.

the study's primary goal was to find the effects of kinesio taping and compression garments on the upper extremity lymphedema following mastectomy. this aim was realized through the current study results, the findings of the current study showed that kinesio taping and compression garments were equally effective on the upper extremity lymphedema following mastectomy.

Eligibility criteria:
inclusion criteria: * • age (45 years-75 years) * patients with edema after 1-year mastectomy * unilateral lymphedema * arm circumference change (arm circumference unilateral than 2 cm or less than 8 cm in comparison with the other side was included) * functional disability or limited movements (shoulder, arm, and hand) exclusion criteria: * • active disease leading to swelling * patients on medications, especially diuretics * allergy * infection * pregnancy * heart and kidney diseases * bilateral lymphedema * skin diseases * cellulitis.